Fosamax (Alendronate) and Osteonecrosis of the Jaw: Understanding Your Legal Options
Latest update (2026-05)
- FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
From General Health Education to Specific Risk Awareness
The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatment options. Within this broad domain, discussions of bone health and osteoporosis management have historically emphasized the benefits of bisphosphonate therapies, including alendronate, marketed as Fosamax. These educational efforts focused on fracture prevention and skeletal integrity, providing a baseline of knowledge for patients and providers. As this informational heritage evolved, clinical observations began to document a rare but serious adverse event: osteonecrosis of the jaw (ONJ) following dental procedures or spontaneous exposure in patients with a history of bisphosphonate use. This shifted the conversation from general therapeutic efficacy to a more targeted concern about long-term medication risks. The transition from broad health education to specific risk awareness naturally leads to questions about legal recourse for affected individuals.
Bridging to Legal Considerations for Fosamax-Related ONJ
For those who have experienced osteonecrosis of the jaw after Fosamax exposure, understanding legal options becomes paramount. The pivot from general health context to occupational exposure concern—here, the patient’s exposure to the medication—requires careful navigation of medical-legal intersections. This transition acknowledges that while the initial health information served an educational purpose, the emergence of adverse outcomes necessitates a focus on accountability and patient rights. The following discussion addresses what to know about legal options for Fosamax-related ONJ, bridging from general awareness to actionable legal considerations.
Medical Evidence: Fosamax and Osteonecrosis of the Jaw
Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Discontinuation of the drug is recommended if severe symptoms develop, and most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical judgment of the treating physician and/or oral surgeon should guide the management plan of each patient based on individual benefit/risk assessment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who develop ONJ while on bisphosphonate therapy should receive care by an oral surgeon (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Research has introduced metrics such as equivalent dose (ED) and threshold dose (TD) as predictive risk assessment tools for medication-related osteonecrosis of the jaw (MRONJ) (https://pubmed.ncbi.nlm.nih.gov/40619534/). In a descriptive study from Iran, ED for each medication was standardized to the cumulative dose of four years of weekly oral alendronate use (4 × 52 × 70 mg = 14,560 mg) (https://pubmed.ncbi.nlm.nih.gov/40619534/). This suggests that cumulative exposure to alendronate, the active ingredient in Fosamax, may be a factor in assessing ONJ risk.
Legal Options for Fosamax-Related ONJ
From a legal perspective, patients who have developed ONJ after Fosamax exposure may consider consulting an attorney to explore their options. Key considerations include the adequacy of warnings provided by the manufacturer regarding the risk of ONJ. The prescribing information for Fosamax includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, patients and attorneys may evaluate whether the warnings were sufficiently prominent and specific to allow informed decision-making. Another important factor is the timeline between Fosamax exposure and documented harm. The time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Additionally, the risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Attorneys may need to document the specific dates of Fosamax use, any dental procedures performed, and the onset of ONJ symptoms to establish a causal link. Patients considering legal action should be aware that most individuals who stop Fosamax after developing severe symptoms experience relief (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset may have recurrence if rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This information may be relevant in assessing damages and the need for ongoing medical care. In summary, Fosamax use has been associated with ONJ, with risk factors including invasive dental procedures, cancer diagnosis, concomitant therapies, poor oral hygiene, and co-morbid disorders (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who develop ONJ should seek care from an oral surgeon (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Legal options may involve evaluating the adequacy of warnings and the timeline between exposure and harm, with potential consultation of an attorney experienced in pharmaceutical litigation.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Fosamax and how is it linked to osteonecrosis of the jaw?
Fosamax (alendronate sodium) is a bisphosphonate medication used to treat osteoporosis. Osteonecrosis of the jaw (ONJ) is a rare but serious condition involving exposed, non-healing bone in the jaw, which has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Risk factors include invasive dental procedures, cancer, and poor oral hygiene.
What legal options are available for individuals who developed ONJ after Fosamax use?
Individuals who developed ONJ after Fosamax exposure may consider consulting an attorney to evaluate potential claims. Key legal considerations include whether the manufacturer provided adequate warnings about the risk of ONJ and whether the timeline between exposure and harm can be established. Attorneys experienced in pharmaceutical litigation can help assess the strength of a case (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
How long after starting Fosamax can ONJ symptoms appear?
The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with longer duration of exposure.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
References
- Fosamax Prescribing Information (DailyMed)
- Fosamax Label (Alternate DailyMed)
- PubMed Study on MRONJ Risk Assessment
Find Out If You Qualify for Compensation
Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.